Rose McNulty

Daraxonrasib, a first-in-class multi-RAS inhibitor, doubles survival in metastatic pancreatic cancer and hints at broader, mutation-agnostic impact.

Tanya Dorff, M.D., breaks down early ABBV-969 data showing strong responses in heavily pretreated mCRPC at ASCO 2026.

Javier Cortes, M.D., Ph.D., discusses KEYNOTE-522 findings showing pembrolizumab plus chemotherapy delivers durable survival gains in high-risk early-stage TNBC after nearly 8 years of follow-up.

Lead ARACOG trial investigator Alicia Morgans, M.D., discusses the importance of including cognitive effects in the conversation around prostate cancer treatment.

New research highlights the role of a factual tone, credible sources, and clinician voices in vaccine-related social media.

Seven-year CROWN trial data show Lorbrena's median PFS is still not reached in advanced ALK-positive NSCLC, with a 94% reduction in intracranial progression risk.

A CDC study found people vaccinated within the past six months were nearly half as likely to transmit SARS-CoV-2 to those they live with.

The advent of checkpoint inhibitors has altered the treatment landscape in urothelial bladder cancer, said Arlene O. Siefker-Radtke, MD, during last week’s NCCN Conference.